Related Experiment Video

Updated: May 21, 2026

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag
08:55

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Published on: December 14, 2017

GST P1, a novel downstream regulator of LRRK2, G2019S-induced neuronal cell death

Jie Chen1, Anthony Liou, Lili Zhang

  • 1State Key Laboratory of Medical Neurobiology and Institute of Brain Sciences, Fudan University School of Medicine, Shanghai, China, 200032.

Frontiers in Bioscience (Elite Edition)
|June 2, 2012
PubMed

Insights

The Parkinson's disease-linked LRRK2 G2019S mutation causes neurotoxicity by suppressing glutathione S-transferase P1 (GSTP1) expression, leading to cell death.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • The LRRK2 G2019S mutation is associated with enhanced neurotoxicity in Parkinson's disease.
  • LRRK2 G2019S overexpression induces caspase-3-dependent apoptosis in neural cells through an unknown pathway.

Purpose of the Study:

  • To elucidate the signaling mechanism underlying LRRK2 G2019S-induced neurotoxicity.
  • To identify specific molecular targets regulated by LRRK2 G2019S.

Main Methods:

  • Investigated the effect of LRRK2 G2019S on gene expression in SH-SY5Y neuronal cells.
  • Utilized promoter hyper-methylation analysis to identify LRRK2 G2019S targets.
  • Employed shRNA-mediated knockdown and overexpression of glutathione S-transferase P1 (GSTP1).

Main Results:

  • LRRK2 G2019S negatively regulated GSTP1 expression transcriptionally via promoter hyper-methylation.
  • Suppression of GSTP1 preceded cell death in LRRK2 G2019S-expressing cells.
  • GSTP1 knockdown exacerbated LRRK2 G2019S neurotoxicity, while GSTP1 overexpression conferred protection.

Conclusions:

  • LRRK2 G2019S triggers neurotoxicity by suppressing GSTP1 expression, contributing to oxidative stress and apoptosis.
  • This study identifies a novel signaling pathway involving GSTP1 in LRRK2-associated neurodegeneration.
  • Findings offer insights into Parkinson's disease pathogenesis and potential therapeutic targets.

More Related Videos

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate11:31

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate

Published on: September 18, 2013

Assaying the Kinase Activity of LRRK2 in vitro06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...